Isis Pharmaceuticals this week said that it stands to receive a $1.1 million payment tied to Alnylam Pharmaceuticals' strategic alliance with Genyzme.
This week, Alnylam announced that it has partnered with Genzyme to develop and commercialize RNAi-based treatments for TTR-mediated amyloidosis. Genzyme will have product rights in Asia (see related story, this issue).
Isis said that the money, to be paid by Alnylam, reflects its share of the upfront fees Alnylam is receiving from Genzyme. Isis is entitled to a portion of payments Alnylam receives on licenses to products enabled by Isis intellectual property pursuant to their ongoing IP cross-licensing arrangement.